WHO Recommendations on GLP-1 Drugs for Obesity Management: A Comprehensive Approach
The World Health Organization has released new recommendations regarding the use of GLP-1 drugs, such as Ozempic, Wegovy, Mounjaro, and Zepbound, to address the global health issue of obesity. A survey conducted in 2024 found that approximately 1 in 8 American adults had tried a GLP-1 drug, with the number of prescriptions increasing. The WHO's guidelines include two key recommendations for the use of these medications.
The first recommendation states that GLP-1 drugs can be used to treat adults with obesity, excluding pregnant women. This recommendation is considered "conditional" due to limited data on the long-term effects of these drugs. More research is needed to understand the consequences of discontinuing the medications and the financial implications of long-term use.
GLP-1 drugs are typically administered through weekly injections and work by targeting hormones that regulate appetite. While drug manufacturers have recently reduced prices, the cost of a monthly dose remains high. The second major recommendation from the WHO emphasizes that GLP-1 drugs should be viewed as a complementary tool in conjunction with other lifestyle changes, such as diet and exercise.
Dr. Francesca Celletti, a senior advisor for obesity at the WHO, highlighted the importance of combining medication with intensive lifestyle modifications. Research suggests that users need to ensure they maintain proper nutrition and engage in physical activity to counteract potential muscle loss caused by the drugs. The WHO stresses that addressing obesity requires not only individual efforts but also societal changes to prevent and manage the condition.
In conclusion, the WHO's new guidance on the use of GLP-1 drugs underscores the need for a comprehensive approach to tackling obesity, combining medication with lifestyle changes and societal interventions. It emphasizes the importance of considering the long-term effects and costs of these medications while promoting a holistic approach to addressing obesity.